LSTA Q1 2022 Earnings — Lisata Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

LSTALisata Therapeutics, Inc.

$44M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$7M

Net Income

-$4M

EPS (Diluted)

$-1.05

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$760,000

Balance Sheet

Total Assets

$91M

Total Liabilities

$3M

Stockholders' Equity

$88M

Cash & Equivalents

$13M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$7M	-$8M	+18.1%
Net Income	-$4M	-$8M	+47.6%